MedTrace Logo

IGF-1 Therapy in Patients With Cystic Fibrosis

NCT00566241 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2013-01-28

No results posted yet for this study

Summary

28 week pilot study to examine the efficacy of recombinant human IGF-1 on body weight and composition in adults with cystic fibrosis.

Conditions

Interventions

DRUG

recombinant human IGF-1

rhIGF-1

DRUG

Placebo

Placebo

Sponsors & Collaborators

Principal Investigators

  • Thomas A Wilson, MD · State Univeristy of New York, Stony Brook, NY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2012-06-30
Completion
2012-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00566241 on ClinicalTrials.gov